Floatz logo

17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE

Temporomandibular Joint Disorder

University of Maryland, BaltimoreSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Temporomandibular Joint Disorder cohort.

Asset / SponsorPhaseRating
Granisetron
Karolinska Institutet
Phase 4BB
Trazodone
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 4BB
Noramitriptyline
Duke University
Phase 2B
Immunoglobulin G, Anti-(Human Calcitonin Gene-Related Peptide Receptor) (Human Monoclonal Heavy Chain), Disulfide With Human Monoclonal Light Chain, Dimer
University of Maryland, Baltimore
Phase 2CCC
Capsaicin
Istanbul University
N/AD
Diclofenac
Istanbul University
N/AD
Ethylicum
University of Florida
N/AD

Same molecule, other indications

17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE is also rated in:

chronic pain syndromeActive
BB
Indicative · Phase 4
70 / 100
View asset →
opiate dependenceDormant
BB
Indicative · Phase 4
69 / 100
View asset →
vertebral column disorderDormant
BB
Indicative · Phase 4
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →